LL-37_Renalexin hybrid peptide exhibits antimicrobial activity at lower MICs than its counterpart single peptides

Julius Kwesi Narh1, Nestor G Casillas-Vega2, Xristo Zarate3

  • 1Facultad de Ciencias Quimicas, Universidad Autonoma de Nuevo Leon, Avenida Universidad s/n, Ciudad Universitaria, 66455, San Nicolas de los Garza, NL, Mexico.

Insights

A new hybrid antimicrobial peptide, LL-37_Renalexin, was developed to combat antibiotic resistance. This novel peptide shows broad-spectrum antibacterial activity against resistant bacteria at lower concentrations than existing agents.

Area of Science:

  • Biochemistry
  • Microbiology
  • Drug Discovery

Background:

  • Antibiotic resistance is a major global health threat, necessitating novel therapeutic strategies.
  • Antimicrobial peptides (AMPs) are promising alternatives to conventional antibiotics due to their antibacterial properties.

Purpose of the Study:

  • To design, produce, and purify a novel multifunctional hybrid antimicrobial peptide, LL-37_Renalexin.
  • To evaluate the antibacterial efficacy of LL-37_Renalexin against clinically relevant bacterial pathogens.

Main Methods:

  • A hybrid peptide (LL-37_Renalexin) was constructed using a GS linker and carrier proteins (SmbP, CusF3H+).
  • Recombinant expression was achieved in Escherichia coli strains (BL21(DE3), SHuffle T7(DE3)).
  • Purification was performed using immobilized metal affinity chromatography.

Main Results:

  • The purified tag-free LL-37_Renalexin demonstrated over 85% reduction in bacterial colony-forming units.
  • Broad-spectrum antimicrobial activity was observed against Staphylococcus aureus, Escherichia coli, MRSA, and Klebsiella pneumoniae.
  • LL-37_Renalexin exhibited lower minimum inhibitory concentrations (10-33 µM) compared to single AMPs (50-100 µM).

Conclusions:

  • The novel hybrid antimicrobial peptide LL-37_Renalexin is effectively expressed and purified.
  • LL-37_Renalexin displays potent broad-spectrum antibacterial activity against clinical isolates.
  • This hybrid peptide represents a promising therapeutic candidate for combating antibiotic-resistant bacteria.